HomeREGULATORY
REGULATORY

10 APIs/17 Products Including Rituxan Biosimilar Added to NHI Price List on Nov. 29
(Nov.29.2017)

The Ministry of Health, Labor and Welfare (MHLW) added 10 APIs/17 products, approved with minor changes to existing products, to the NHI reimbursement price list on November 29, including a biosimilar version of Chugai Pharmaceutical’s anticancer drug Rituxan (rituximab) ...
(LOG IN FOR FULL STORY)

News Calendar